Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on June 1, 2026. The filing serves as a Regulation FD disclosure regarding a presentation used to assist discussions about the Harmonic Phase 2 clinical trial for the company's product candidate, LP-300.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a regulatory disclosure regarding clinical trial discussions and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing is limited to the disclosure of a presentation related to the Harmonic Phase 2 trial.
Guidance, Outlook, and Risks
Management Commentary: The company utilized a presentation (Exhibit 99.1) to discuss the Harmonic Phase 2 clinical trial for LP-300.
Forward-Looking Statements: The information in Item 7.01 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liabilities of that section unless expressly incorporated by specific reference.
Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K filing.
Investor Verification Checklist
- Review Exhibit 99.1 to access the full presentation regarding the Harmonic Phase 2 clinical trial for LP-300.
- Verify the status and timeline of the LP-300 Phase 2 trial through subsequent press releases or clinical trial registries.
- Check for any future filings that may incorporate the presentation data by specific reference.
- Confirm the company's cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.